Roche Aug 11, 2022 Roche Nabs FDA Label Expansion for Ventana CDx Panel Jul 21, 2022 Roche Sees More Growth Opportunities for Phesgo, Tecentriq; Still Optimistic on Tiragolumab Premium Jul 14, 2022 Synthetic Control Arms Finding Stronger Footing in Precision Oncology Trials, Regulatory Submissions Premium Jul 1, 2022 Treos Bio, Roche Begin Combination Immunotherapy Study in Microsatellite-Stable Colorectal Cancer Jun 10, 2022 Norway's Fledgling Precision Oncology Effort Finding Early Success Premium Jun 10, 2022 In Brief This Week: Kazia Therapeutics, ImaginAb, Roche, ASCO, HealthVerity, Massive Bio, AdhereTech Jun 9, 2022 FDA Approves Foundation Medicine Test as CDx With Roche's Rozlytrek Jun 6, 2022 Foundation Medicine, Arvinas Partner to Develop CDx For Prostate Cancer Drug Jun 3, 2022 Foundation Medicine to Provide Comprehensive Genomic Profiling Tests in Lung Cancer Screening Trial Jun 2, 2022 Roche Garners Rights to Repare's ATR Inhibitor for $125M Upfront May 25, 2022 NICE Recommends Keytruda, Chemo Combo for Advanced TNBC, Narrows PD-L1 Expression Threshold May 19, 2022 UPenn Researchers Find Low Uptake of Janssen's Balversa in Eligible Bladder Cancer Patients Premium May 11, 2022 Roche Immunotherapy Combo Misses Progression-Free Survival Endpoint in First-Line NSCLC Trial May 6, 2022 Drugmakers Come Together Hoping to Formalize MRD as Surrogate Endpoint in AML Trials Apr 13, 2022 Precision Cancer Consortium Launches With Bayer, GSK, Roche, Novartis as Founding Members Mar 25, 2022 Roche, Bristol Myers Squibb Partner on Digital Pathology Algorithms, Assays for Cancer Diagnosis Mar 22, 2022 FDA Approves Merck's Keytruda for MSI-H, dMMR Endometrial Cancer With Roche CDx Feb 3, 2022 Roche Q4 Pharmaceutical Revenues Up 14 Percent as Perjeta Maintains Top Spot Among Oncology Drugs Jan 5, 2022 Rain Therapeutics to Study Milademetan, Tecentriq Combo in CDKN2A-Altered Solid Tumors Nov 19, 2021 European Commission Approves Roche's Gavreto for RET Fusion-Positive NSCLC Load More Breaking News FDA Approves Taiho Oncology's Lytgobi for FGFR2-Rearranged Bile Duct Cancer Gladstone Institute Joins With Parker Institute on New Center to Study CRISPR-Based Cell Therapies Meliora Therapeutics Raises $11M in Seed Financing In Brief This Week:Â Verismo Therapeutics, Fore Biotherapeutics, Merck, Caris Life Sciences Tumor-Only Sequencing Found to Overestimate Mutational Burden in Non-European Patients Atara Biotherapeutics to Net $30M From Pierre Fabre for European Tab-Cel Approval
